Get the Stockscreener App
0.00
100.00%
-9.81
Allovir Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).
See More
Previous Close:
$9.81
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$49.48M
Revenue:
-
Net Income/Loss:
$-168.86M
P/E Ratio:
0.00
EPS:
-1.68
Net Cash Flow:
$-125.29M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$24.15
Allovir Inc Stock (ALVR) Company Profile
Name
Allovir Inc
Sector
Industry
Phone
(617) 433-2605
Address
1100 WINTER STREET, WALTHAM
Compare ALVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.00 | 49.48M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.93 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.54 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.89 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.35 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.18 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-26-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-23 | Downgrade | JP Morgan | Overweight → Underweight |
| Dec-22-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-18-23 | Initiated | BofA Securities | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | JP Morgan | Overweight |
| Aug-24-20 | Initiated | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | SVB Leerink | Outperform |
View All
Allovir Inc Stock (ALVR) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
AlloVir, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsALVR - Louisiana First News
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - marketscreener.com
AlloVir ($ALVR) Is Paying a Settlement to Investors — Here’s How to Get Your Share - TradingView
William Blair Initiates Kalaris Therapeutics With Outperform Rating - MarketScreener
(ALVR) Technical Data - news.stocktradersdaily.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board chair - Investing.com India
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - The Manila Times
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Trend Tracker for (ALVR) - Stock Traders Daily
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States DelveInsight Report | Ansun Biopharma, AlloVir, MedImmune - The Globe and Mail
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionALVR - Marketscreener.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
ALLOVIR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Announces Closing of Merger with AlloVir - The Manila Times
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
(ALVR) On The My Stocks Page - Stock Traders Daily
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
AlloVir shareholders approve merger with Kalaris Therapeutics By Investing.com - Investing.com Australia
AlloVir Stockholders Approve Key Amendment and Merger - TipRanks
AlloVir shareholders approve merger with Kalaris Therapeutics - Investing.com
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
AlloVir (ALVR) Expected to Announce Earnings on Thursday - The AM Reporter
AlloVir Inc. (ALVR) reports earnings - Quartz
Allovir, Inc. SEC 10-K Report - TradingView
How To Trade (ALVR) - Stock Traders Daily
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline - ACCESS Newswire
FINAL ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on AlloVir, Inc. (ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - ACCESS Newswire
Allovir Inc Stock (ALVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):